Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2015', provides an overview of the Chagas Disease (American Trypanosomiasis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chagas Disease (American Trypanosomiasis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chagas Disease (American Trypanosomiasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chagas Disease (American Trypanosomiasis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chagas Disease (American Trypanosomiasis) Overview 8
Therapeutics Development 9
Pipeline Products for Chagas Disease (American Trypanosomiasis) - Overview 9
Pipeline Products for Chagas Disease (American Trypanosomiasis) - Comparative Analysis 10
Chagas Disease (American Trypanosomiasis) - Therapeutics under Development by Companies 11
Chagas Disease (American Trypanosomiasis) - Therapeutics under Investigation by Universities/Institutes 12
Chagas Disease (American Trypanosomiasis) - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Chagas Disease (American Trypanosomiasis) - Products under Development by Companies 15
Chagas Disease (American Trypanosomiasis) - Products under Investigation by Universities/Institutes 16
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development 17
Anacor Pharmaceuticals, Inc. 17
Eisai Co., Ltd. 18
Grupo Praxis Pharmaceutical SA 19
Merck & Co., Inc. 20
Panacela Labs, Inc. 21
Sanofi 22
Seek 23
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
benznidazol - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
chagas disease vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
chagas disease vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
chagas disease vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cz-007 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cz-008 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs for Chagas Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
E-1224 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EPLBS-1246 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EPLBS-967 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
fexinidazole - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
K-777 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LH-7 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Monoclonal Antibody for Chagas - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NEU-321 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
posaconazole - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules for Chagas Disease - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules for Chagas Disease - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules for Chagas Disease - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules for Chagas Disease - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Infectious Diseases - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Protozoal Infections - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VNI - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
XELRYX-3 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Chagas Disease (American Trypanosomiasis) - Recent Pipeline Updates 63
Chagas Disease (American Trypanosomiasis) - Dormant Projects 65
Chagas Disease (American Trypanosomiasis) - Discontinued Products 66
Chagas Disease (American Trypanosomiasis) - Product Development Milestones 67
Featured News & Press Releases 67
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 67
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 67
May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world 69
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 70
Mar 12, 2012: DNDi Receives £2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2015 9
Number of Products under Development for Chagas Disease (American Trypanosomiasis) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Chagas Disease (American Trypanosomiasis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 17
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co., Ltd., H1 2015 18
Chagas Disease (American Trypanosomiasis) - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2015 19
Chagas Disease (American Trypanosomiasis) - Pipeline by Merck & Co., Inc., H1 2015 20
Chagas Disease (American Trypanosomiasis) - Pipeline by Panacela Labs, Inc., H1 2015 21
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H1 2015 22
Chagas Disease (American Trypanosomiasis) - Pipeline by Seek, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Chagas Disease (American Trypanosomiasis) Therapeutics - Recent Pipeline Updates, H1 2015 63
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H1 2015 65
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H1 2015 66